Brief: 4D Molecular Therapeutics Announces FDA Clearance Of Ind Application For 4D-150 Genetic Medicine For The Treatment Of Diabetic Macular Edema
02/02/2023 22:15
Feb 2 (Reuters) - 4D Molecular Therapeutics Inc
FDMT.O :
* 4D MOLECULAR THERAPEUTICS ANNOUNCES FDA CLEARANCE OF IND
APPLICATION FOR 4D-150 GENETIC MEDICINE FOR THE TREATMENT OF
DIABETIC MACULAR EDEMA
* 4D MOLECULAR THERAPEUTICS INC - RANDOMIZED PHASE 2 PORTION
OF
PHASE 1/2 PRISM CLINICAL TRIAL WITH 4D-150 FOR WET AMD IS
CURRENTLY ENROLLING
Source text for Eikon: ID:nGNX95fd8r
Further company coverage: FDMT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on 4D Molecular Therapeutics
See all news4D Molecular Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
4D Molecular Therapeutics Q2 net loss widens
Brief: 4D Molecular Therapeutics Q2 Net Income USD -72.936 Million Vs. IBES Estimate USD -70.3 Million
4D Molecular Therapeutics Inc expected to post a loss of $1.02 a share - Earnings Preview
Brief: 4d Molecular Therapeutics Says 4D-150 Continues To Be Well Tolerated With No New Safety Findings